Last reviewed · How we verify
NCT05414929: CUTE-IPS
Acceptability of HPV Self-sampling Among Canadian Women Aged 21 to 65
NA trial testing HPV self-sampling in HPV Infection in 400 participants. Status unknown.
15 May 2022
Quick facts
| Lead sponsor | Université de Sherbrooke |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 400 |
| Start date | 4 April 2022 |
| Primary completion | 15 May 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- HPV self-sampling
Conditions studied
- HPV Infection — all drugs for HPV Infection →
- Cervical Cancer Screening — all drugs for Cervical Cancer Screening →
Sponsor
Université de Sherbrooke — full company profile →
Who can join
Adults 21 to 65, female only, with HPV Infection or Cervical Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We propose a cross-sectional study to explore the acceptability and feasibility of HPV self-sampling among Quebec women. The study will invite eligible women to self-sample for HPV at home. The HPV risk factors of patients included in the study will be taken into consideration (vaccination, smoking, number of partners, date of last screening, etc.).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05414929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HPV self-sampling
Trials testing the same drug.
- NCT03222817 — HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals · NA · completed
- NCT04401670 — Cervical Cancer Screening in Cameroon · NA · completed
- NCT03012932 — HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women · NA · completed
Other recruiting trials for HPV Infection
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
- NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting
Other Université de Sherbrooke trials
Trials by the same sponsor.
- NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
- NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
- NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05414929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
- Last refreshed: 10 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05414929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing